Clin Gastroenterol H:患有和没有炎症性肠病妇女怀孕所需时间的比较

2019-09-04 xing.T MedSci原创

由此可见,研究人员发现患有IBD的女性,尤其是那些接受过CD手术的女性,与没有IBD的女性相比,其怀孕的时间显著增加。这表明IBD女性的生育能力下降。

患者在生育高峰期经常被诊断炎症性肠病(IBD)。近日,消化病领域权威杂志Clinical Gastroenterology and Hepatology发表了一篇研究文章,研究人员在丹麦一项针对女性的人群研究中调查了IBD如何影响生育能力。 

研究人员收集了丹麦国家出生队列的数据,这是一项全国性的研究,从1996年到2002年共招募了92274名孕妇。一直在积极尝试怀孕的妇女在妊娠大约16周时通过计算机辅助电话采访报告了她们的怀孕所需时间。有关IBD的信息来自丹麦国家患者登记处。使用回归模型和调整重要的混杂因素,研究人员比较了患有和没有IBD的女性的怀孕时间。

研究人员计算了无IBD女性74471次妊娠、溃疡性结肠炎(UC)女性340次妊娠、克罗恩病(CD)女性206次妊娠的怀孕时间。与非IBD女性妊娠相比,IBD、UC和CD女性怀孕所需时间超过12个月的调整相对风险比率分别为1.28(95%CI为0.99-1.65)、1.10(95%CI为0.80-1.51)和1.54(95%CI为1.03-2.30)。对于在受孕前接受CD手术的妇女与非IBD妊娠相比,调整后的相对风险比为2.54(95%CI为1.39-4.65)。在受孕前进行手术的UC患者太少,无法对该组进行有意义的分析。

由此可见,研究人员发现患有IBD的女性,尤其是那些接受过CD手术的女性,与没有IBD的女性相比,其怀孕的时间显著增加。这表明IBD女性的生育能力下降。 

原始出处:

Sonia Friedman,et al.Comparison of Time to Pregnancy in Women With and Without Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology.2019.https://www.cghjournal.org/article/S1542-3565(19)30906-1/fulltext

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072681, encodeId=031120e268170, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 10 15:11:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712074, encodeId=70e01e1207423, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Nov 01 00:11:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064815, encodeId=a03f206481583, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Aug 15 10:11:00 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547263, encodeId=0bb0154e2639c, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 07:11:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2019-09-10 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072681, encodeId=031120e268170, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 10 15:11:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712074, encodeId=70e01e1207423, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Nov 01 00:11:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064815, encodeId=a03f206481583, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Aug 15 10:11:00 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547263, encodeId=0bb0154e2639c, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 07:11:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072681, encodeId=031120e268170, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 10 15:11:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712074, encodeId=70e01e1207423, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Nov 01 00:11:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064815, encodeId=a03f206481583, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Aug 15 10:11:00 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547263, encodeId=0bb0154e2639c, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 07:11:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072681, encodeId=031120e268170, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 10 15:11:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712074, encodeId=70e01e1207423, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Nov 01 00:11:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2064815, encodeId=a03f206481583, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Aug 15 10:11:00 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547263, encodeId=0bb0154e2639c, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri Sep 06 07:11:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]

相关资讯

2019 亚洲工作组指南:饮食和炎症性肠病

亚洲工作组饮食和炎症性肠病指南主要介绍了亚洲国家IBD临床营养的多学科管理。指南主要基于现有的出版的文献证据,针对IBD的营养支持治疗以及初级营养治疗的相关数据提出了用于指导IBD患者营养支持治疗的38条实践建议。

Clin Gastroenterol H:降低炎症性肠病患者再住院率的危险因素和干预措施

由此可见,对于接受IBD治疗的患者,30天和90天再入院率分别为18.1%和26.0%。IBD急性发作和感染是再入院的常见原因,疼痛控制不足和需要肠外营养是常见的危险因素。需要进行干预性研究以降低再入院风险。

儿童炎症性肠病诊断和治疗专家共识

近年来,我国儿童炎症性肠病(IBD)发病率显著升高。国内及国际对儿童IBD诊治的研究进展很快,IBD的诊治水平有了很大提高。中华医学会儿科学分会消化学组和临床营养学组专家借鉴国外最新共识以及国内儿童IBD的临床研究和实践,在更新完善2010年儿童IBD诊断规范共识意见上增加治疗内容,形成新的诊治共识,为IBD患儿的临床管理提供指导意见。

Diabetes Care:二肽基肽酶4抑制剂与炎症性肠病风险

由此可见,基于人群的美国成人糖尿病队列研究表明,短期DPP4i治疗不会增加IBD风险。

JAMA Pediatr:患炎症性肠病的儿童患精神疾病的风险增加

根据瑞典Karolinska研究所发表于JAMA Pediatrics的一项新研究显示,患有炎症性肠病(IBD)的儿童患精神疾病的风险更大。

GUT:肾素-血管紧张素系统(RAS)与炎症性肠病

研究认为RAS介导人类细胞的纤维化并在肠道炎症中受到干扰,靶向该系统的药物与改善疾病结局有关